Insmed Inc at Nasdaq Investor Conference Transcript
Okay. Great. Well, thanks for staying for the next session. I'm pleased to have Will Lewis, the CEO of Insmed with us here. Just a reminder, before we get started, I have to just make a disclosure statement. Remember that personal holdings disclosures can be found on the Morgan Stanley website at morganstanley.com/researchdisclosures. And with that, I'm going to turn it over to Will to make a couple of opening comments on the pillars of the company, and then we'll jump into Q&A.
Thank you very much. I appreciate the opportunity to be here. Insmed is in an interesting place because we've just come off our strongest quarter in our history, and I've been at the company for 10 years now, and we think of ourselves as being made up of 4 pillars. One is ARIKAYCE, our approved product for the treatment of refractory MAC lung disease. It's approved in the U.S., Europe and Japan. We built out our own commercial
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
